Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Active not recruiting 5Withdrawn 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Pancreatic Neoplasms 4Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Glioblastoma 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Brain Neoplasms 2Xeroderma Pigmentosum 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Papillomavirus Infections 1Neuroblastoma 1

Interventions

pembrolizumab 6avelumab 4Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ALT-803 2yeast-CEA vaccine 1vadimezan 1trebananib 1obinutuzumab 1naptumomab estafenatox 1erdafitinib 1enfortumab vedotin 1bicalutamide 1atezolizumab 1Ultrasonography 1Specimen Handling 1Ramucirumab 1Radiosurgery 1Phantoms, Imaging 1PM 01183 1Omacor 1Nivolumab 1Neoadjuvant Therapy 1Mitomycin 1Lycopene 1Leucovorin 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Transitional Cell × Specimen Handling × Clear all
NCT05564416 2025-10-21

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

National Cancer Institute (NCI)

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡